Glenmark Pharmaceuticals has informed that it attached media release today titled ‘Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg’.
The above information is a part of company’s filings submitted to BSE.